Brammer acquisition bolsters Thermo Fisher place in the market

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: Thermo fisher scientific, Brammer Bio, cell and gene therapy, CDMO

Thermo Fisher’s $1.7bn acquisition bolsters its ‘already strong position’ in the cell and gene therapy market, with increased CDMO capabilities.

On March 25, 2019, Thermo Fisher Scientific acquired Brammer Bio for $1.7bn​ (€1.5bn) establishing itself further in the cell and gene therapy sector.

The acquisition of the contract development and manufacturing organization (CDMO) Brammer Bio, which specializes in viral vector manufacturing for gene and cell therapies, saw Thermo Fisher Scientific add the company to its pharma services business.

We spoke with a Thermo Fisher spokesperson in regards to this recent agreement and how it places the company in the cell and gene therapy arena.

“Thermo Fisher Scientific has a unique position serving the pharmaceutical and biotech industry and one of the areas that our customers are most excited about, and asking for the most assistance with, is enabling gene therapy,”​ the spokesperson told us.

Per the acquisition, Thermo Fisher will expand its CDMO capabilities and add to its “already strong position in the gene therapy market.”​ The company stated it supports the market with its cell culture media, single-use technologies for bioprocessing, analytical instrumentation and related consumables.

The spokesperson added, “Given our commercial scale and strong customer relationships, we also believe that we can meaningfully contribute to driving industry standardization in gene therapies to effectively support this rapidly growing market.”

According to Thermo Fisher, the gene therapy market is currently worth approximately $1bn, with an estimated growth rate of 25%. The company added that it believes that around 60-70% of the market is outsourced to CDMOs.

They added, “This is a very attractive market that's growing rapidly given the robust pipeline of new gene therapies in development – roughly 700, which has basically doubled over the past three years.”

“The ultimate goal is to accelerate the process to get these medicines to patients faster,” ​the spokesperson concluded. 

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars